We are Readily3D, we developed Tomolite and Apparite to make research in biosciences quicker and more efficient. Founded in 2020, Readily3D originates from a research work started in 2017 at Ecole Polytechnique Fédérale de Lausanne. Existing bioprinting technologies are slow, which tends to reduce cell viability. They also have a poor ability to produce complex anatomical structures, such as vasculatures. To overcome these limitations, we created Tomolite: a unique bioprinter, allowing biologists to print an entire cell-laden volume at once, in less than a minute and without impairing cell viability.
Currently, our team collaborates with biologists to explore innovative applications of tomographic 3D printing in biosciences. Since 2019, pilot tests of Tomolite and Apparite have begun in European life sciences laboratories. We are continuously looking for more users to further explore the potential of our technology.
Paul Delrot
Co-founder and CEO
Paul co-invented the volumetric bioprinting technology at the end of his PhD studies at EPFL in 2017. After transferring what was a lab experiment into a standalone and user-friendly 3D printer, Paul co-founded Readily3D in 2020. Since then, Paul has focused on demonstrating the wide range of applications enabled by volumetric bioprinting while leading product development at Readily3D.
Leoni El Sahili
Sales Executive
Leoni is a seasoned international manager with a proven track record in engineering, information technology and biotechnology. A graduate from INSA Toulouse with a Specialized Industrial Business Management Masters, Leoni has a strong business and sales acumen. As Sales Executive at Readily3D, Leoni's is on a mission to accelerate the development of the volumetric bioprinting market worldwide.
Christophe Moser
Co-founder and advisor
Christophe Moser joined EPFL as associate professor in 2010, after co-founding Ondax Inc. in 2000 (acquired by Coherent) and before co-founding Composyt Light Labs in 2014 (acquired by Intel). Since 2020, he is board member of Readily3D and has an advisory role.
Gracinda Silva
Operations Manager
With extensive experience in supply chain management, Gracinda supports the team in implementing all the necessary actions for a constant efficiency of Readily3D's operations.
Max Kollep
R&D Engineer
Max is in charge of developing and optimizing the future products at Readily3D. Max's work lies at the crossroads of optics and chemistry, which fits his versatile background (MSc Microengineering, EPFL).
Haley Owsianko
Computer Science Engineer
Haley is in charge of the continuous improvement of Readily3D's tomographic printing algorithms. She's graduating from EPFL in Computer Science. Her work spans the fields of computational engineering, physically based rendering and distributed computing.
Let us know! Give us a call or write to us – we will be more than happy to assist you.
Interested in our products? Reach out to us and we will provide you with a quote.
Feel free to contact us and we will schedule an online meeting to discuss our products.
We are Readily3D, we developed Tomolite and Apparite to make research in biosciences quicker and more efficient. Founded in 2020, Readily3D originates from a research work started in 2017 at Ecole Polytechnique Fédérale de Lausanne. Existing bioprinting technologies are slow, which tends to reduce cell viability. They also have a poor ability to produce complex anatomical structures, such as vasculatures. To overcome these limitations, we created Tomolite: a unique bioprinter, allowing biologists to print an entire cell-laden volume at once, in less than a minute and without impairing cell viability.
Currently, our team collaborates with biologists to explore innovative applications of tomographic 3D printing in biosciences. Since 2019, pilot tests of Tomolite and Apparite have begun in European life sciences laboratories. We are continuously looking for more users to further explore the potential of our technology.
Paul Delrot
Co-founder and CEO
Paul co-invented the volumetric bioprinting technology at the end of his PhD studies at EPFL in 2017. After transferring what was a lab experiment into a standalone and user-friendly 3D printer, Paul co-founded Readily3D in 2020. Since then, Paul has focused on demonstrating the wide range of applications enabled by volumetric bioprinting while leading product development at Readily3D.
Leoni El Sahili
Sales Executive
Leoni is a seasoned international manager with a proven track record in engineering, information technology and biotechnology. A graduate from INSA Toulouse with a Specialized Industrial Business Management Masters, Leoni has a strong business and sales acumen. As Sales Executive at Readily3D, Leoni's is on a mission to accelerate the development of the volumetric bioprinting market worldwide.
Christophe Moser
Co-founder and advisor
Christophe Moser joined EPFL as associate professor in 2010, after co-founding Ondax Inc. in 2000 (acquired by Coherent) and before co-founding Composyt Light Labs in 2014 (acquired by Intel). Since 2020, he is board member of Readily3D and has an advisory role.
Gracinda Silva
Operations Manager
With extensive experience in supply chain management, Gracinda supports the team in implementing all the necessary actions for a constant efficiency of Readily3D's operations.
Max Kollep
R&D Engineer
Max is in charge of developing and optimizing the future products at Readily3D. Max's work lies at the crossroads of optics and chemistry, which fits his versatile background (MSc Microengineering, EPFL).
Haley Owsianko
Computer Science Engineer
Haley is in charge of the continuous improvement of Readily3D's tomographic printing algorithms. She's graduating from EPFL in Computer Science. Her work spans the fields of computational engineering, physically based rendering and distributed computing.
Let us know! Give us a call or write to us – we will be more than happy to assist you.
Interested in our products? Reach out to us and we will provide you with a quote.
Feel free to contact us and we will schedule an online meeting to discuss our products.